Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world
  • Posted by Rachel Howard
  • October 22, 2020
  • Articles

How will COVID-19 affect uptake of vaccinations against other diseases?

How will COVID-19 affect uptake of vaccinations against other diseases?

As the world waits anxiously for a SARS-CoV-2 vaccine, Director Rachel Howard explores whether COVID-19 will help or hinder the quest to increase uptake of other vaccinations. Published in PME Magazine, October 2020

In January, as the (then unnamed) novel coronavirus started spreading across the globe, media coverage in the Western world urged people not to panic, reminding them that ‘regular’ flu posed a greater threat to their health. Now we find ourselves in October, over six months since the first lockdown, and with many countries now undergoing a ‘second wave’ of infections. With the benefit of hindsight, it might seem easy to scoff at the following quote from Dr William Schaffner, a professor of preventive medicine and health policy at Vanderbilt University Medical Center in Tennessee. “When we think about the relative danger of this new coronavirus and influenza, there’s just no comparison. Coronavirus will be a blip on the horizon in comparison. The risk is trivial.”

read more »

How we used our proprietary ChoiceQual conjoint technique to assess and develop a market access and pricing strategy for an influenza vaccine

How we used our proprietary ChoiceQual conjoint technique to assess and develop a market access and pricing strategy for an influenza vaccine

Our client required pricing research to better inform their pricing and access strategy for their influenza vaccine product. They wanted to understand how the attributes for Product X may or may not drive a price premium across a range of geographies and how future positioning and real world evidence availability might impact price and willingness to pay (WTP).

read more »

  • Posted by Suzan Serip, Artemis Rizoglou, Brett Gardiner
  • August 4, 2020
  • Articles

The race to secure a SARS-CoV-2 vaccine: big promises linked to big(ger) deals

The race to secure a SARS-CoV-2 vaccine: big promises linked to big(ger) deals

Market Access Director Brett Gardiner, Consultant Suzan Serip and Analyst Artemis Rizoglou explore the various SARS-CoV-2 vaccine supply deals that have been struck around the world.

As clinical trials for SARS-CoV-2 vaccines are still ongoing and final results are not expected until earlier than this autumn, in recent months we have witnessed an increasing amount of supply deals between governments and vaccine manufacturers.

read more »

How we helped our client maximise uptake and fine-tune the marketing strategy for their vaccine product in China

How we helped our client maximise uptake and fine-tune the marketing strategy for their vaccine product in China

Our client’s vaccine to protect against a condition prevalent in older adults had recently launched and secondary research was required to enable them to understand more about their target healthcare consumer and attitudes to health, well-being and vaccination. They needed to build a complete picture of how consumers are influenced, such as whether they are more influenced by HCP advice or online forums and social media. Furthermore they needed to develop an understanding for other out-of-pocket (OOP) competitor vaccines and what the future healthcare initiatives mean for vaccination in general.
 

read more »

How we supported forecasting for a new vaccine by identifying the optimal pricing strategy

How we supported forecasting for a new vaccine by identifying the optimal pricing strategy

Our client was looking to identify the price point that would maximise revenue from their new vaccine across 8 emerging markets in Latin America and Asia Pacific, as well as establish long-term projections for their forecasting model. In parallel, they needed to ensure widespread and rapid market penetration of the vaccine, taking into account factors such as consumer socio-economic group, age and household composition.
 

read more »